Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials
Journal articles
- Journal
Lincoff, AM; Tcheng, JE; Miller, DP; Booth, JE; Montague, EA; Topol, EJ
Published in: CIRCULATION
October 15, 1996
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 15, 1996
Volume
94
Issue
8
Start / End Page
2185 / 2185
Publisher
AMER HEART ASSOC
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Lincoff, A. M., Tcheng, J. E., Miller, D. P., Booth, J. E., Montague, E. A., & Topol, E. J. (1996). Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. CIRCULATION, 94(8), 2185–2185.
Lincoff, A. M., J. E. Tcheng, D. P. Miller, J. E. Booth, E. A. Montague, and E. J. Topol. “Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials.” CIRCULATION 94, no. 8 (October 15, 1996): 2185–2185.
Lincoff AM, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. CIRCULATION. 1996 Oct 15;94(8):2185–2185.
Lincoff, A. M., et al. “Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials.” CIRCULATION, vol. 94, no. 8, AMER HEART ASSOC, Oct. 1996, pp. 2185–2185.
Lincoff AM, Tcheng JE, Miller DP, Booth JE, Montague EA, Topol EJ. Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials. CIRCULATION. AMER HEART ASSOC; 1996 Oct 15;94(8):2185–2185.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 15, 1996
Volume
94
Issue
8
Start / End Page
2185 / 2185
Publisher
AMER HEART ASSOC
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology